3M Co. (MMM) 10-K Red Flags
Risk signals extracted deterministically from 3M Co.’s SEC 10-K/10-Q XBRL filings — no LLM, every finding cites the underlying data.
Detected red flags (14)
- Restatement of financial statements: The term "restatement of" "previously issued" appears in 4 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- R&D intensity declining: R&D as % of revenue fell from 4.1% to 2.8%. This may signal reduced innovation investment — potentially impacting long-term competitive position. Compare with peer R&D trends.
- Endogenous analysis: 1 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 6 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- Ongoing high-severity risk language: Restatement of financial statements.
- Revenue grew **+1.5%** YoY to $24.95B.
- 5-year revenue CAGR **-6.7%**; 10y CAGR -2.1%.
- Market cap $93.31B at $180.94 per share.
- Trailing P/E 30.16, P/S 3.74, P/B 31.61.
- Composite risk: Elevated.
- Leverage debt/equity 4.27 (high).
- Restatement of financial statements: The term "restatement of" "previously issued" appears in 4 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- R&D intensity declining: R&D as % of revenue fell from 4.1% to 2.8%. This may signal reduced innovation investment — potentially impacting long-term competitive position. Compare with peer R&D trends.
Filings & ownership
- Latest annual report (10-K) filed Feb 3, 2026.
- Latest quarterly report (10-Q) filed Jul 21, 2026.
- 9 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 5 sell transactions — net selling $4.3M.
- ~10,000+ recent 13F-HR filings reference 3M Co.; broad institutional reporting.
- Recent filers include Pendal Group Ltd, AM INVESTMENT PARTNERS LLC, FMR LLC.
- 20 recent 13G passive institutional ownership notices.
Full MMM analyst report
Valuation (DCF & Graham), technicals, macro exposure, risk scorecard and 13F/13D ownership.
View full report →Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.